Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Bob Biersack who wrote (89299)	3/21/2000 6:10:00 AM
From: blackmerlin	Respond to of 120523

CYTO: Imaging Agent Added to Oncology Treatment Guidelines-The NCCN guidelines have a major influence on what treatments Oncologist should consider for a patient based on extensive scientific data. This is very important for Cytogen because it will drive Physician's attention to ProstaScint, moves ProstaScint to top of the list of possible treatment options, and influences what HMOs and co-payers, etc., will reimburse for a patient. This listing definitely affects an Oncologist's practice at many levels and is a big plus for Cytogen (see below). Regards, Jake Blackmerlin "Cytogen's Prostate Cancer Imaging Agent Added to Oncology Treatment Guidelines National Comprehensive Cancer Network Includes ProstaScint In Newly Issued Oncology Practice Guidelines PRINCETON, N.J., Mar 20, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO ) announced that the National Comprehensive Cancer Network (NCCN) has added the use of the Company's ProstaScint(R) imaging agent to its Practice Guidelines for Prostate Cancer. NCCN guidelines are the most widely recognized and used guidelines in cancer care. The new guidelines were announced at the NCCN's Fifth Annual Conference late last week. The NCCN is an alliance of the nation's leading cancer centers and was established to enhance the leadership role of member institutions in the managed care environment. "The incorporation of ProstaScint into the new NCCN guidelines underscores the place of our cancer imaging agent in the diagnosis of prostate cancer," said Nicholas Borys, M.D., Cytogen's Vice President of Medical Affairs. "Although marketing of ProstaScint began in the U.S. in 1997, some physicians and insurance carriers have considered this imaging technology as experimental. Now, with the publication of the NCCN guidelines, ProstaScint is well positioned as a mainstream diagnostic tool. We look forward to working with the NCCN to disseminate this information to patients, physicians and healthcare payors." "These guidelines are important to patients, because the NCCN recommends that ProstaScint be considered in the clinical evaluation of the majority of men who exhibit evidence of recurrent prostate cancer, and for selected patients with newly diagnosed disease," said Michael J. Manyak, M.D., Professor and Chairman, Department of Urology, George Washington Medical Center. ProstaScint imaging agent identifies the extent of prostate cancer in newly diagnosed patients at high risk for metastatic spread of the disease and for patients with recurrent prostate cancer. ProstaScint employs a monoclonal antibody linked to a radioactive isotope and directed to prostate specific membrane antigen -- PSMA, the Company's proprietary cancer marker. Cytogen Corporation, based in Princeton, New Jersey, is a biopharmaceutical company that develops new treatments and diagnostics for cancer and urological diseases. Cytogen has three products on the market including ProstaScint(R) imaging agent for prostate cancer, Quadramet(R) agent for treatment of pain from cancers that have metastasized to the bone, and OncoScint(R) imaging agent for colorectal and ovarian cancers. Cytogen also holds the intellectual property rights to PSMA (Prostate Specific Membrane Antigen), a unique antigen under development for immunotherapeutic and other approaches, particularly in the area of prostate cancer. AxCell Biosciences, a wholly owned subsidiary of Cytogen, is charting the proteome to develop a protein pathway database to identify novel drug targets. For information on Cytogen, including prescribing information regarding its approved products, visit the Company's web sites at cytogen.com and axcellbio.com . Information in this press release which is not historical is forward-looking and involves risks and uncertainties. Actual results may differ materially for various reasons, including acceptance of the guidelines as to ProstaScint by the physician community, by healthcare payors, and managed care organizations, our success in marketing the product, acceptance of the product by physicians, reimbursement of expenses for the scan, and other factors discussed in the Company's filings with the Securities and Exchange Commission. SOURCE Cytogen Corporation"